Efficacy of CA125 for endometriosis-associated ovarian cancers
| Author (year) | Endometriosis-associated ovarian cancers | Benign endometrioma | CA125 n (%) | P- value | Cut-off value | Sensitivity | Specificity | |||
| n | Median (range) | CA125 n (%) | n | Median (range) | ||||||
| Malkasian et al20 (1988) | 68 | 297.3 (6.8–10000) | <35 U/mL 15 (32.1) | 90 | 14.8 (0.0–2221.6) | <35 U/mL 72 (80.0) | N/A | 65 U/mL | 0.89–0.92 | 0.75 to 0.83 |
| ≧35 U/mL 53 (77.9) | ≧35 U/mL 18 (20.0) | |||||||||
| ≧65 U/mL 51 (75.0) | ≧65 U/mL 7 (7.8) | |||||||||
| ≧100 U/mL 50 (73.5) | ≧100 U/mL 4 (4.4) | |||||||||
| Shimada et al21 (2007) | 40 | 524.4 | <35 U/mL 13 (32.5) | 127 | N/A | <35 U/mL 41 (32.0) | N/A | 95 U/mL | 0.60 | 0.79 |
| ≧35 U/mL 27 (69.5) | ≧35 U/mL 86 (68.0) | |||||||||
| ≧500 U/mL 10 (25.0) | ||||||||||
| Wang et al28 (2013) | 17 | 122.9 (6–573.4) | <35 U/mL 8 (47.1) | N/A | ||||||
| ≧35 U/mL 9 (52.9) | ||||||||||
| Taniguchi et al26 (2014) | 33 | <50 U/mL 17 (52.0) | N/A | |||||||
| 50–100 U/mL 27 (69.5) | ||||||||||
| >100 U/mL 10 (30.0) | ||||||||||
| Kadan et al27 (2015) | 37 | 58 (8–1755) | 50 | 39.5 (4–736) | 0.1* | |||||
*As compared by Wilcoxon rank-sum test.
N/A, not applicable.